# Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis

> **NCT01340586** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 18 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** Apixaban
- **DRUG:** Apixaban

## Key facts

- **NCT ID:** NCT01340586
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2011-09
- **Final completion:** 2011-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2016-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01340586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01340586, "Pharmacokinetics and Pharmacodynamics of Apixaban in Subjects on Hemodialysis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01340586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*